Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion

Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.  

Statue of Liberty
Shining A Light On Sobi's Growth In The US • Source: Shutterstock

More from Deals

More from Business